| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Nylidrin hydrochloride is an agonist of β-adrenergic receptors. It binds to β-adrenergic receptors with a Kg of 0.37 μM. It also acts as an antagonist of NR1A/2B subunit-containing NMDA receptors. Additionally, it inhibits IgE-mediated histamine release from mast cells and basophils.
|
|---|---|
| ln Vitro |
In vitro, Nylidrin hydrochloride effectively inhibits IgE-mediated release of histamine from passively sensitized rat peritoneal mast cells and human basophils. It also inhibits IgG1-mediated histamine release from passively sensitized guinea pig lung slices. These activities highlight its antiallergic properties.
|
| ln Vivo |
Nylidrin hydrochloride has been used as a hypotensive drug in the treatment of arterial hypertension in pregnancy. It has been applied to hypertensive women in advanced pregnancy as a betamimetic for tocolysis. Its vasodilatory effects contribute to its in vivo pharmacological actions.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Nylidrin hydrochloride typically involve radioligand binding studies to determine its affinity for β-adrenergic receptors. The Kg value of 0.37 μM is derived from such binding experiments. Functional assays measuring receptor-mediated signaling pathways can also be used.
|
| Cell Assay |
In vitro cellular assays for Nylidrin hydrochloride involve studying its effects on histamine release from mast cells and basophils. Cells are passively sensitized with IgE, and the inhibition of histamine release upon compound treatment is measured. These assays quantify the compound's antiallergic activity.
|
| Animal Protocol |
In vivo animal experiments for Nylidrin hydrochloride have been performed in rat models to study its effects on histamine release. It has also been used in clinical studies involving hypertensive pregnant women. Its tocolytic and hypotensive effects have been evaluated in these settings.
|
| ADME/Pharmacokinetics |
Nylidrin hydrochloride is soluble in DMSO (≥41 mg/mL) and water (~5 mg/mL). It is administered orally or via other routes depending on the indication. Its pharmacokinetic properties, such as absorption and metabolism, are consistent with its use as a therapeutic agent for peripheral vascular disorders and other conditions.
|
| Toxicity/Toxicokinetics |
Nylidrin hydrochloride has been shown to be an effective inhibitor of histamine release. It has been used clinically, suggesting an acceptable safety profile for its approved indications. Detailed toxicological data is not provided in the search results, but its use as a therapeutic agent implies established safety parameters.
|
| Additional Infomation |
Nylidrin hydrochloride is an alkylbenzene compound belonging to the β-adrenergic agonist class. Nylidrin causes peripheral vasodilation, positive inotropic effects, and increases gastric juice secretion. It is used to treat peripheral vascular disease and preterm birth.
Nylidrin hydrochloride is a beta-adrenergic agonist with peripheral vasodilatory and antiallergic properties. It has been used clinically for peripheral vascular disorders and premature labor. Its mechanism involves β-adrenergic receptor agonism and inhibition of histamine release. |
| Molecular Formula |
C19H26CLNO2
|
|---|---|
| Molecular Weight |
335.87
|
| Exact Mass |
335.165
|
| CAS # |
849-55-8
|
| PubChem CID |
5702098
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
111ºC
|
| LogP |
4.617
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
296
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.OC1C=CC(C(C(C)NC(CCC2C=CC=CC=2)C)O)=CC=1
|
| InChi Key |
CLJHABUMMDMAFA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H25NO2.ClH/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17;/h3-7,10-15,19-22H,8-9H2,1-2H3;1H
|
| Chemical Name |
4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol;hydrochloride
|
| Synonyms |
Arlidin Hydrochloride; Arlidin; Nylidrin hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 41 mg/mL (~122.07 mM)
H2O : ~5 mg/mL (~14.89 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9773 mL | 14.8867 mL | 29.7734 mL | |
| 5 mM | 0.5955 mL | 2.9773 mL | 5.9547 mL | |
| 10 mM | 0.2977 mL | 1.4887 mL | 2.9773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
